title: Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?
authors.affiliation: University of Melbourne Department of Medicine, St Vincent's Hospital , Fitzroy, Victoria , Australia.
authors.forename: Frank
authors.initials: F
authors.lastname: Firkin
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects*; D002277:Carcinoma / Q000209:etiology*; D002291:Carcinoma, Papillary; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications*; D016609:Neoplasms, Second Primary / Q000209:etiology*; D010087:Oxides / Q000009:adverse effects*; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide